View the Webcast Presentation

Please note that this Web cast uses Flash v.7 and streaming video. For optimal viewing, a high speed internet connection (i.e., DSL, ISDN or Cable) is recommended.

Get CME/CE Credit

Once you have viewed the presentation, please login to take the post-survey and test.

Statement of Need

The development of target-specific therapies has led to major advances in the treatment of acute myeloid leukemia (AML), in particular with regard to five-year survival rates. Despite these advances, clinicians in the community setting still face challenges in managing patients who are older than 65 years of age and who are more likely to have multiple co-morbidities, poorer performance status, unfavorable cytogenetics, or who express multi-drug resistance. Unfortunately, clinical trials do not always address these challenges in their study designs, leading to a potential gap between the data in the trials and the reality of treating this group of patients. Clinicians are thus faced with making difficult decisions in an environment where information sharing can provide a true benefit in patient care outcomes.

Through this informative and interactive program, clinicians will be able to review the latest findings in AML research and apply these principles in context to their everyday practice. By bringing together local oncologists and utilizing the latest technological advances to deliver CE, PESG will bring the “clinic” to the web, providing a peer-to-peer, interactive, case-based educational forum that emphasizes interactive discussion and sharing of best practices.

Learning Objectives

At the conclusion of this continuing medical education activity, participants should be able to:

Identify factors that may complicate the treatment of AML in older patients
Discuss the molecular and cytogenetic pathogenesis of AML in the context of newer therapies to manage this disease
Develop treatment strategies for patients with relapsed or refractory AML or for those with multiple co-morbidities
Apply new information on targeted therapies and “best practices” in treatment strategies into clinical practice

Program Faculty

David L. Grinblatt, MD (Program Chair)
Associate Professor of Medicine
Feinberg School of Medicine
Northwestern University, Division of Hematology
Evanston Northwestern Healthcare
Evanston, Illinois

Dr. Abul Islam, MD, PhD, FRCPath, FACP
(Program Facilitator)
Attending Physician and Researcher
Division of Hematology and Oncology
Buffalo General Hospital
Buffalo, New York

Target Audience

This continuing medical education activity is intended for community oncologists who treat patients with AML, or other healthcare professionals with an interest in the management of this disease.

Disclosure Statements

It is the policy of Professional Education Services Group that the faculty and sponsor disclose real or apparent conflicts of interest relating to the topics of this educational activity and also disclose discussion of unlabeled/unapproved uses of drugs or devices.

David L. Grinblatt
Honorarium: Pharmion Corporation
Abul Islam
Dr. Islam has no significant financial relationships or conflicts of interest to report.
Professional Education Services Group
PESG has received an independent educational grant from Wyeth Pharmaceuticals in support of the development of this activity.
Off-label Disclosure
Many of the therapies discussed in this program may include information with regard to both on-label and off-label use in AML or other hematological malignancies.

Accreditation Information

Physicians: Professional Education Services Group is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. This activity has been planned and implemented in accordance with the Essential Areas and policies of the ACCME.

PESG designates this educational activity for a maximum of 2.0 AMA PRA Category 1 Credits^TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Nurses: This activity for 2.4 contact hours is provided by Professional Education Services Group, which is accredited as a provider of continuing education in nursing by the American Nurses Credentialing Center’s Commission on Accreditation. Activity number 07310.

Pharmacists: Professional Education Services Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Program Number 829-000-06-016-H01-P. This program provides 2.00 contact hours (0.20 CEUs) of continuing education credit. Continuing education statements of credit are available to participants online after successful completion of a CE posttest and program evaluation form. Initial release date: 7/28/06. Program expiration date: 7/28/09